SCHEMBL2621471

SCHEMBL2621471

CCCCC/C=C\C/C=C\CCCCCCCC(C)=O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.73
PPARG P37231 5/20 0.73
F7 P08709 4/20 0.73
F3 P13726 4/20 0.73
KDM4E B2RXH2 4/20 0.73
PPARD Q03181 4/20 0.73
PPARA Q07869 4/20 0.73
FFAR1 O14842 3/20 0.73
FABP3 P05413 3/20 0.73
PTGS1 P23219 2/20 0.73
LMNA P02545 2/20 0.73
CYP3A4 P08684 2/20 0.73
CYP19A1 P11511 2/20 0.73
FABP4 P15090 2/20 0.73
HPGD P15428 2/20 0.73
ALOX15 P16050 2/20 0.73
AKR1C3 P42330 2/20 0.73
NR4A2 P43354 2/20 0.73
HSD17B10 Q99714 2/20 0.73
TDP1 Q9NUW8 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18325614 1.00 ALDH1A1 (0.73) ALDH1A1PPARGF7F3KDM4E
SCHEMBL15908483 1.00 ALDH1A1 (0.73) ALDH1A1PPARGF7F3KDM4E
SCHEMBL15908480 1.00 ALDH1A1 (0.73) ALDH1A1PPARGF7F3KDM4E
SCHEMBL15908489 1.00 ALDH1A1 (0.73) ALDH1A1PPARGF7F3KDM4E
SCHEMBL15908476 1.00 ALDH1A1 (0.73) ALDH1A1PPARGF7F3KDM4E
SCHEMBL11893268 1.00 ALDH1A1 (0.73) ALDH1A1PPARGF7F3KDM4E
SCHEMBL9183242 1.00 ALDH1A1 (0.73) ALDH1A1PPARGF7F3KDM4E
SCHEMBL3414485 1.00 ALDH1A1 (0.73) ALDH1A1PPARGF7F3KDM4E
SCHEMBL21302754 1.00 ALDH1A1 (0.73) ALDH1A1PPARGF7F3KDM4E
SCHEMBL10740192 0.98 PPARG (0.72) ALDH1A1PPARGF7F3KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024019953-A1 METHOD OF ENHANCING RECOVERY FROM LONG COVID Synaptogenix, Inc. (US) 2024-01-25 WO disclosed
US-20230332071-A1 MACROCYCLIC MUSK LACTONES AND USES THEREOF PHYTO TECH CORP. 2023-10-19 US disclosed
US-20230323244-A1 MACROCYCLIC MUSK LACTONES AND USES THEREOF PHYTO TECH CORP (US) 2023-10-12 US disclosed
US-20230295617-A1 METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS WAVE LIFE SCIENCES LTD. (SG) 2023-09-21 US disclosed
US-20230295617-A1 METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS WAVE LIFE SCIENCES LTD. (SG) 2023-09-21 US disclosed
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230232884-A1 NUTRITIONAL FORMULA BUILDING BLOCK NUTRITIONALS, LLC (US) 2023-07-27 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed
US-11639483-B2 Macrocyclic musk lactones and uses thereof PHYTO TECH CORP. (US) 2023-05-02 US disclosed
US-20220401467-A1 OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2022-12-22 US disclosed
EP-1909918-B1 SKIN LIGHTENING COMPOSITIONS AROMTECH LTD (FI) 2013-09-04 EP disclosed
US-8455421-B2 Compositions and methods for the removal of chewing gum residues from substrates EXPELLIERE INT LTD (GB) 2013-06-04 US disclosed
US-20120136049-A1 ANTIBACTERIAL AGENT OSAKA UNIVERSITY (JP) 2012-05-31 US disclosed
US-20120095075-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-04-19 US disclosed
US-20120027796-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS ALNYLAM PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
US-20110319309-A1 COMPOSITIONS AND METHODS FOR THE REMOVAL OF CHEWING GUM RESIDUES FROM SUBSTRATES ENVIROWAYS TECHNOLOGIES LIMITED (GB) 2011-12-29 US disclosed
US-20110046599-A1 Multi-Day Delivery Of Biologically Active Substances SAMOS PHARMACEUTICALS LLC 2011-02-24 US disclosed
US-20110046599-A1 Multi-Day Delivery Of Biologically Active Substances SAMOS PHARMACEUTICALS LLC 2011-02-24 US disclosed
US-20110003889-A1 MEMBRANE FUSION INHIBITOR KAIHATSU, Kunihiro (JP) 2011-01-06 US disclosed
US-20090005508-A1 EPOXIDIZED ESTERS OF VEGETABLE OIL FATTY ACIDS AS REACTIVE DILUENTS ARCHER-DANIELS-MIDLAND COMPANY 2009-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639483-B2 Macrocyclic musk lactones and uses thereof MGLL, UGCG, DAGLA ALDH1A1 2005/4885PPARG 347/4885F7 2573/4885
US-20110046599-A1 Multi-Day Delivery Of Biologically Active Substances GUSB, SERPINA6, CD44 ALDH1A1 957/4885PPARG 2727/4885F7 1549/4885
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 ALDH1A1 1330/4885PPARG 271/4885F7 4629/4885
US-20230232884-A1 NUTRITIONAL FORMULA FABP2, ALOX5, LPO ALDH1A1 3812/4885PPARG 467/4885F7 532/4885
US-20230295617-A1 METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS ELOVL6, ELOVL5, ELOVL1 ALDH1A1 2846/4885PPARG 86/4885F7 3470/4885
US-20230323244-A1 MACROCYCLIC MUSK LACTONES AND USES THEREOF MGLL, UGCG, DAGLA ALDH1A1 2005/4885PPARG 347/4885F7 2573/4885
US-20220401467-A1 OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF TLR9, RNGTT, NT5C3B ALDH1A1 4085/4885PPARG 2903/4885F7 3960/4885
US-20120136049-A1 ANTIBACTERIAL AGENT TEAD4, ELOVL6, TEAD1 ALDH1A1 677/4885PPARG 18/4885F7 3497/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 ALDH1A1 2528/4885PPARG 498/4885F7 3177/4885
US-20120095075-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS CETP, LCAT, NPC1L1 ALDH1A1 3847/4885PPARG 1038/4885F7 2424/4885
US-20230332071-A1 MACROCYCLIC MUSK LACTONES AND USES THEREOF MGLL, UGCG, DAGLA ALDH1A1 2005/4885PPARG 347/4885F7 2573/4885
US-20120027796-A1 NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS CETP, ABCB4, LCAT ALDH1A1 4201/4885PPARG 1391/4885F7 1406/4885
US-20110003889-A1 MEMBRANE FUSION INHIBITOR FLOT1, NSF, VAMP7 ALDH1A1 2332/4885PPARG 370/4885F7 1204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.